Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

February 20, 2026

Study Completion Date

August 20, 2027

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

ZM001 Injection

ZM001 injection, 2.5× 10\^7 CAR-T cells, 5× 10\^7 CAR-T cells, 1× 10\^8 CAR-T cells and 2× 10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.

All Listed Sponsors
collaborator

Peking Union Medical College Hospital

OTHER

lead

Beijing Immunochina Medical Science & Technology Co., Ltd.

INDUSTRY